# Q-Line Biotech share price today (Q-Line Biotech Ltd, NSE: QLINE) > Q-Line Biotech share price today: ₹396.80 at the NSE close on 20 November 2026. Q-Line Biotech (NSE: QLINE) is worth ₹926 crore and trades at a P/E of 16.9. > Q-Line Biotech Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. QLINE · Trading · data as of 20 November 2026. Page: https://www.sectoralpha.in/stocks/q-line-biotech-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹396.80 - P/E: 16.9× (lower than 100% of the last 6 months) - Revenue (Sep 2026): ₹152 Cr (+5.6% on a year ago) - Profit (Sep 2026): ₹20.0 Cr (−4.8% on a year ago) - Operating margin: 26.3% (+1.3 points on a year ago) - ROCE: 22%, FY26 Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business. ## What is the Q-Line Biotech share price today? Q-Line Biotech Ltd's share price was ₹396.80 at the close on 20 November 2026. It is in an uptrend that has just slipped below its 200-day average. That is 26.9% below its average price over the last 200 trading days. Since its first close in our records, on 12 June 2026, it has traded between ₹397 and ₹726, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Over the last 5 months the share price moved −22% while the NIFTY 500 moved +5%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Q-Line Biotech's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Q-Line Biotech reported revenue of ₹152 crore, up 5.6% from ₹144 crore a year earlier, and a profit of ₹20.0 crore, down 4.8% from ₹21.0 crore. ### Q-Line Biotech results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹152 crore | ₹144 crore | +5.6% | | Profit | ₹20.0 crore | ₹21.0 crore | −4.8% | | Earnings per share | ₹8.40 | ₹13.10 | −35.9% | | Operating margin | 26.3% | 25.0% | +1.3 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Q-Line Biotech's management discussed these results on a call held on 13 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Q-Line Biotech share price history? Q-Line Biotech closed at ₹396.80 on 20 November 2026. Its highest weekly close since June 2026 was ₹726.20 on 11 September 2026. ### Q-Line Biotech share price: then and now | When | Close | Change to 20 Nov 2026 | | --- | --- | --- | | 1 week ago · 13 Nov 2026 | ₹488.30 | −18.7% | | 1 month ago · 19 Oct 2026 | ₹600.55 | −33.9% | | Earliest weekly close in our records · 12 Jun 2026 | ₹509.30 | −22.1% | | Highest weekly close since June 2026 · 11 Sep 2026 | ₹726.20 | −45.4% | | Lowest weekly close since June 2026 · 20 Nov 2026 | ₹396.80 | 0.0% | Weekly closing prices. Each change is the move from that price to the 20 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (26 weekly closes from 12 June 2026 to 20 November 2026.) ## What is the latest news on Q-Line Biotech? 20 Nov 2026: Q-Line Biotech closed at ₹396.80, down 18.7% on the week and down 33.9% on the month. 13 Nov 2026: Q-Line Biotech held its results call for July to September 2026. Management guided: FY27 and FY28 revenue growth 25-30% each year led by reagents, instruments and CDMO. ### Earlier - Results for July to September 2026: Revenue up 5.6% and profit down 4.8% on a year earlier. ## What dividend does Q-Line Biotech pay? Q-Line Biotech has paid no dividend on the NSE since its first NSE close in our records (12 June 2026), the start of the period we checked. No. Q-Line Biotech Ltd paid out 0% of its profit as dividends in each of its last 4 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 20 November 2026.) ## What did Q-Line Biotech management say on the latest results call? On the call for July to September 2026, held on 13 November 2026, Q-Line Biotech's management guided: FY27 and FY28 revenue growth 25-30% each year led by reagents, instruments and CDMO. > “Therefore, we are very confident about the 400 crore number. There is no doubt about it.” > Ajay Kumar Mohanty, on the call for July to September 2026 ### What management guided - Steady-state operating profit 28% for FY27 with profit 15-16% as H2 interest savings ₹4-5 crore offsets Unit-4 depreciation. - Unit-4 operations H2FY27 at 25-30% capacity, ₹150-160 crore FY27 and ₹250 crore FY28, ₹120 crore minimum up to ₹250-300 crore on Class C/D. - Heidelco FY27 revenue around ₹130 crore on critical-care scale and synergies. - Chemiluminescence January to March 2027, Q-Count autoloader November and Hb meter invoices month-end on NODs. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/59475-13-Nov-2026.pdf). (From the call for July to September 2026, 13 November 2026.) ## What to watch in Q-Line Biotech's next results? When Q-Line Biotech reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Pending government instrument orders converting once consignee lists arrive - delivery in H2 print versus further deferral. Management raised each of these on the latest results call. - Pending government instrument orders converting once consignee lists arrive - delivery in H2 print versus further deferral. - Unit-4 progressing to full H2 operations on pending licences - licence build and kit output versus slip. - European principal CDMO order shipping with follow-on volumes - dispatch and reorder versus one-off in coming quarters. - Heidelco stake closing and consolidation - shareholder approval and SPA terms versus lapse in next quarter. ## Which stock lists is Q-Line Biotech on? Q-Line Biotech is not on any of our India lists this week. ## Is Q-Line Biotech profitable? Q-Line Biotech Ltd earned ₹20.0 Cr of net profit in the Sep 2026 quarter, −4.8% on the same quarter a year earlier. Full-year FY26 profit was ₹56.0 Cr. Over 3 years profit has grown 20.5% a year on average. The Sep 2026 quarter's profit is 13.2% of that quarter's revenue. The same quarter a year earlier earned ₹0.0 Cr. For the full year, FY26 profit was ₹56.0 Cr (+194.7% on the year before). ## How much revenue does Q-Line Biotech make, and is it growing? Q-Line Biotech Ltd reported ₹152 Cr of revenue in the Sep 2026 quarter, +5.6% on the same quarter a year earlier. Over 3 years it has grown 23.2% a year on average. The last full year, FY26, came in at ₹342 Cr. FY26 revenue was ₹342 Cr, +9.3% on the year before. Recent pace: the last four quarters grew −1.6% on average, against 23.2% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every ₹100 of sales does Q-Line Biotech keep? Q-Line Biotech Ltd's operating margin was 26.3% in the Sep 2026 quarter, 1.3 percentage points higher than the same quarter a year ago. Across 4 years it has been between 18.6% and 28.7%. The latest quarter is within that range. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Q-Line Biotech's profit turning into cash? Over the last 3 years, 8% of Q-Line Biotech Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹16.0 Cr of operating cash against ₹56.0 Cr of profit. After ₹36.0 Cr of spending on assets, free cash was −₹20.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 8% of profit came in as cash: the cash cycle got 169 days longer between FY23 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 169 days longer. The next section looks at where the cash is stuck. ## Where does Q-Line Biotech's cash go? Q-Line Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 251 days in FY26, up from 82 days in FY23. It spent ₹155 Cr on assets over the last 3 years. Customers take 134 days to pay, and stock sits for 258 days on average. At FY26 sales of ₹342 Cr, each day of that cycle ties up about ₹0.9 Cr, so roughly ₹235 Cr is tied up in the business at any time. FY26: customers took 134 days to pay and stock sat for 258 days, about 8.5 months of sales sitting as stock, for a full cycle of 251 days, longer than FY23's 82. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 258 days. Customers pay about 134 days after that. Suppliers are paid at 142 days. Together that makes the 251-day cycle. Spending on assets: ₹155 Cr over the last 3 years, against ₹22.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹19.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Q-Line Biotech's P/E ratio, and how does it compare with its own history? Q-Line Biotech Ltd's P/E is 16.9×, about the lowest it has ever been. Its usual P/E (the middle reading) is 22.8×, over 6 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Q-Line Biotech business getting better or worse? Q-Line Biotech Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Q-Line Biotech earn on its capital? Q-Line Biotech Ltd earned a ROCE of 22% in FY26. That is up from a low of 16% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 16.4% net margin and 0.61× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 16.4% net margin × 0.61× asset turnover × 2.27× leverage (assets divided by equity) ≈ 22.7% on equity. The margin does most of the work; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 49% on reported income across 2 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Q-Line Biotech have too much debt? Q-Line Biotech Ltd had ₹225 Cr of borrowings against ₹246 Cr of equity in FY26, so its debt is 0.91× its equity. Its operating profit is 5 times its interest bill. Over 3 years borrowings went from ₹74.0 Cr to ₹225 Cr. Over the last 3 of those years it spent ₹155 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Q-Line Biotech shareholding pattern? No group of Q-Line Biotech Ltd's owners changed its stake by a full percentage point over the last 2 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Q-Line Biotech from balance-sheet trouble? For Q-Line Biotech Ltd, the Z-score is left out, because it comes from the second data source we could not check, and a safety score is not worth showing when two sources disagree. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Q-Line Biotech rank in its industry? 59.9 out of 100, rank 48 of 65 in Trading, with 31% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Q-Line Biotech Ltd scores 59.9 out of 100 against the 65 companies it is compared with in Trading, ranking 48. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 21.8 + 24.9 + 13.2 = 59.9 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Q-Line Biotech compared with? Q-Line Biotech ranks 48 of 65 Trading companies on the 4-Factor Sector Score, with 59.9 out of 100. 1. [Shankara Buildpro Ltd](https://www.sectoralpha.in/stocks/shankara-buildpro-ltd) BUILDPRO · quiet · Most evidence points up · 63% evidence 68.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.4/43.75 · Revenue 30.2% · Profit 38% · Operating margin change 0.3 points · 100% evidence Capital efficiency 23.2/31.25 · ROCE 39% (year to Mar 2026) · Operating margin 3.4% · 100% evidence Valuation 13.4/25 · P/E 15.2× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.4 + 23.2 + 13.4 = 68 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 2. [Mangalam Global Enterprise Ltd](https://www.sectoralpha.in/stocks/mangalam-global-enterprise-ltd) MGEL · breaking out · Most evidence points up · 83% evidence 65.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidence Capital efficiency 14.8/25 · ROCE 17% (year to Mar 2026) · Operating margin 2.3% · 100% evidence Valuation 10.8/20 · P/E 15.1× · PEG n/a · 15% evidence Relative strength 17.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.6% · Strength vs NIFTY 500 (same reading) 19.3% · 1 year 19% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.4 + 14.8 + 10.8 + 17.9 = 65.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Nupur Recyclers Ltd](https://www.sectoralpha.in/stocks/nupur-recyclers-ltd) NRL · leader · Most evidence points up · 82% evidence 65.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 79.3% · Profit 71.5% · Operating margin change 2.9 points · 95% evidence Capital efficiency 15.0/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 9.9% · 76% evidence Valuation 7.8/20 · P/E 59.7× · PEG n/a · 50% evidence Relative strength 19.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 76.1% · Strength vs NIFTY 500 (same reading) 90.2% · 1 year 196.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 15 + 7.8 + 19.7 = 65.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Rashi Peripherals Ltd](https://www.sectoralpha.in/stocks/rashi-peripherals-ltd) RPTECH · losing its lead · Evidence leans up · 82% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.0/35 · Revenue 51.1% · Profit 93.2% · Operating margin change 1.1 points · 95% evidence Capital efficiency 15.1/25 · ROCE 17% (year to Mar 2026) · Operating margin 3.6% · 76% evidence Valuation 10.8/20 · P/E 11.1× · PEG n/a · 50% evidence Relative strength 11.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.2% · Strength vs NIFTY 500 (same reading) 15.3% · 1 year 98% · 100% evidence · 9 of 12 weeks ahead Exact sum: 27 + 15.1 + 10.8 + 11.7 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Bhatia Communications & Retail (India) Ltd](https://www.sectoralpha.in/stocks/bhatia-communications-retail-indialtd) turning · Evidence leans up · 72% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 55.2% · Profit 72.1% · Operating margin change 1.5 points · 95% evidence Capital efficiency 18.6/25 · ROCE 21.3% (year to Mar 2026) · Operating margin 5.7% · 95% evidence Valuation 9.3/20 · P/E 25.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 39.8% · 1 year n/a · 25% evidence · 1 of 1 week ahead Exact sum: 23.9 + 18.6 + 9.3 + 11.8 = 63.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 6. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) turning · Too little evidence to rank firmly · 57% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 100% · Profit 100% · Operating margin change -0.2 points · 71% evidence Capital efficiency 16.2/25 · ROCE 23.5% (year to Mar 2026) · Operating margin 1.6% · 95% evidence Valuation 11.4/20 · P/E 1.1× · PEG n/a · 15% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 100.1% · 1 year n/a · 25% evidence · 1 of 1 week ahead Exact sum: 23.6 + 16.2 + 11.4 + 12.3 = 63.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Arisinfra Solutions Ltd](https://www.sectoralpha.in/stocks/arisinfra-solutions-ltd) ARIS · breaking out · Evidence leans up · 60% evidence 63.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.7/35 · Revenue 41.7% · Profit 100% · Operating margin change 3 points · 95% evidence Capital efficiency 13.8/25 · ROCE 15.6% (year to Mar 2026) · Operating margin 11.7% · 76% evidence Valuation 10.4/20 · P/E 18.5× · PEG n/a · 15% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 13.6% · 1 year 8.9% · 25% evidence · 11 of 12 weeks ahead Exact sum: 27.7 + 13.8 + 10.4 + 11.2 = 63.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dhunseri Ventures Ltd](https://www.sectoralpha.in/stocks/dhunseri-ventures-ltd) DVL · breaking out · Evidence leans up · 74% evidence 61.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue 21.4% · Profit 100% · Operating margin change 82 points · 71% evidence Capital efficiency 11.1/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 12.8/20 · P/E 3.5× · PEG n/a · 50% evidence Relative strength 15.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 14.8% · 1 year 3.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.8 + 11.1 + 12.8 + 15.6 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [SG Mart Ltd](https://www.sectoralpha.in/stocks/sg-mart-ltd) SGMART · leader · Evidence leans up · 83% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidence Capital efficiency 11.6/25 · ROCE 10.2% (year to Mar 2026) · Operating margin 4.6% · 100% evidence Valuation 9.2/20 · P/E 91.1× · PEG n/a · 15% evidence Relative strength 18.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 43.2% · Strength vs NIFTY 500 (same reading) 56.8% · 1 year 214.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22 + 11.6 + 9.2 + 18.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DC Infotech & Communication Ltd](https://www.sectoralpha.in/stocks/dc-infotech-communication-ltd) DCI · quiet · Evidence leans up · 75% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 33.9% · Profit 37.6% · Operating margin change -0.3 points · 100% evidence Capital efficiency 16.6/25 · ROCE 23% (year to Mar 2026) · Operating margin 5.2% · 100% evidence Valuation 10.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 11.1/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 12.1% · 1 year n/a · 25% evidence · 6 of 8 weeks ahead Exact sum: 22.9 + 16.6 + 10.1 + 11.1 = 60.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [Singer India Ltd](https://www.sectoralpha.in/stocks/singer-india-ltd) SINGERIND · breaking out · Evidence leans up · 68% evidence 60.0 out of 100 Growth Capital Valuation Relative 12. [Ivalue Infosolutions Ltd](https://www.sectoralpha.in/stocks/ivalue-infosolutions-ltd) IVALUE · quiet · Evidence leans up · 78% evidence 58.3 out of 100 Growth Capital Valuation Relative 13. Aayush Art and Bullion Ltd leader · Too little evidence to rank firmly · 59% evidence 58.0 out of 100 Growth Capital Valuation Relative 14. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) VIESL · losing its lead · Too little evidence to rank firmly · 60% evidence 57.6 out of 100 Growth Capital Valuation Relative 15. [Patel Retail Ltd](https://www.sectoralpha.in/stocks/patel-retail-ltd) PATELRMART · breaking out · Evidence leans up · 68% evidence 57.4 out of 100 Growth Capital Valuation Relative 16. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) TEMBO · quiet · Evidence leans up · 71% evidence 57.2 out of 100 Growth Capital Valuation Relative 17. [Euro Pratik Sales Ltd](https://www.sectoralpha.in/stocks/euro-pratik-sales-ltd) EUROPRATIK · basing · Evidence leans up · 68% evidence 55.2 out of 100 Growth Capital Valuation Relative 18. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) PROSTARM · quiet · Evidence leans up · 68% evidence 54.7 out of 100 Growth Capital Valuation Relative 19. [Mardia Samyoung Capillary Tubes Company Ltd](https://www.sectoralpha.in/stocks/mardia-samyoung-capillary-tubes-company-ltd) MSCTC · Evidence leans up · 60% evidence 52.5 out of 100 Growth Capital Valuation Relative 20. BMW Ventures Ltd BMW · breaking out · Evidence leans up · 60% evidence 51.7 out of 100 Growth Capital Valuation Relative 21. [MMTC Ltd](https://www.sectoralpha.in/stocks/mmtc-ltd) MMTC · quiet · Evidence leans up · 86% evidence 50.9 out of 100 Growth Capital Valuation Relative 22. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) TRANSCHEM · turning · Evidence leans up · 60% evidence 50.7 out of 100 Growth Capital Valuation Relative 23. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) SHIVAUM · breaking out · Evidence leans up · 67% evidence 50.5 out of 100 Growth Capital Valuation Relative 24. [Cropster Agro Ltd](https://www.sectoralpha.in/stocks/cropster-agro-ltd) CROPSTER · Evidence leans down · 60% evidence 49.6 out of 100 Growth Capital Valuation Relative 25. [Sudarshan Pharma Industries Ltd](https://www.sectoralpha.in/stocks/sudarshan-pharma-industries-ltd) quiet · Evidence leans down · 87% evidence 48.9 out of 100 Growth Capital Valuation Relative 26. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) HEXATRADEX · quiet · Evidence leans down · 74% evidence 44.9 out of 100 Growth Capital Valuation Relative 27. [Adani Enterprises Ltd](https://www.sectoralpha.in/stocks/adani-enterprises-ltd) ADANIENT · quiet · Evidence leans down · 93% evidence 44.4 out of 100 Growth Capital Valuation Relative 28. [A-1 Ltd](https://www.sectoralpha.in/stocks/a-1-ltd) A1L · Evidence leans down · 60% evidence 43.5 out of 100 Growth Capital Valuation Relative 29. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) BPAGRI · basing · Too little evidence to rank firmly · 57% evidence 43.1 out of 100 Growth Capital Valuation Relative 30. [Lloyds Enterprises Ltd](https://www.sectoralpha.in/stocks/lloyds-enterprises-ltd) LLOYDSENT · quiet · Evidence leans down · 75% evidence 40.9 out of 100 Growth Capital Valuation Relative 31. [Shanti Overseas (India) Ltd](https://www.sectoralpha.in/stocks/shanti-overseas-indialtd) SHANTI · Evidence leans down · 61% evidence 39.0 out of 100 Growth Capital Valuation Relative 32. [Riddhi Siddhi Gluco Biols Ltd](https://www.sectoralpha.in/stocks/riddhi-siddhi-gluco-biols-ltd) quiet · Evidence leans down · 87% evidence 37.4 out of 100 Growth Capital Valuation Relative 33. [Fabtech Technologies Ltd](https://www.sectoralpha.in/stocks/fabtech-technologies-ltd) FABTECH · basing · Evidence leans down · 68% evidence 37.0 out of 100 Growth Capital Valuation Relative 34. [PTC India Ltd](https://www.sectoralpha.in/stocks/ptc-india-ltd) PTC · quiet · Evidence leans down · 82% evidence 35.8 out of 100 Growth Capital Valuation Relative 35. [Uniphos Enterprises Ltd](https://www.sectoralpha.in/stocks/uniphos-enterprises-ltd) UNIENTER · basing · Evidence leans down · 75% evidence 35.8 out of 100 Growth Capital Valuation Relative 36. [Hardwyn India Ltd](https://www.sectoralpha.in/stocks/hardwyn-india-ltd) HARDWYN · quiet · Evidence leans down · 90% evidence 35.7 out of 100 Growth Capital Valuation Relative 37. [Shah Foods Ltd](https://www.sectoralpha.in/stocks/shah-foods-ltd) quiet · Too little evidence to rank firmly · 53% evidence 34.5 out of 100 Growth Capital Valuation Relative 38. Manbro Industries Ltd Too little evidence to rank firmly · 52% evidence 33.4 out of 100 Growth Capital Valuation Relative 39. [BN Agrochem Ltd](https://www.sectoralpha.in/stocks/bn-agrochem-ltd) BNAGROCHEM · basing · Most evidence points down · 64% evidence 33.2 out of 100 Growth Capital Valuation Relative 40. [Kothari Industrial Corporation Ltd](https://www.sectoralpha.in/stocks/kothari-industrial-corporation-ltd) KOTIC · quiet · Too little evidence to rank firmly · 53% evidence 33.2 out of 100 Growth Capital Valuation Relative 41. [Neueon Corporation Ltd](https://www.sectoralpha.in/stocks/neueon-corporation-ltd) NEUEON · quiet · Too little evidence to rank firmly · 56% evidence 32.1 out of 100 Growth Capital Valuation Relative 42. [Oswal Agro Mills Ltd](https://www.sectoralpha.in/stocks/oswal-agro-mills-ltd) OSWALAGRO · basing · Most evidence points down · 60% evidence 30.6 out of 100 Growth Capital Valuation Relative 43. [Le Merite Exports Ltd](https://www.sectoralpha.in/stocks/le-merite-exports-ltd) LEMERITE · Too little evidence to rank firmly · 58% evidence 26.5 out of 100 Growth Capital Valuation Relative 44. [Yogi Ltd](https://www.sectoralpha.in/stocks/yogi-ltd) YOGI · turning · Most evidence points down · 70% evidence 24.9 out of 100 Growth Capital Valuation Relative 45. [Pervasive Commodities Ltd](https://www.sectoralpha.in/stocks/pervasive-commodities-ltd) breaking out · Too little evidence to rank firmly · 47% evidence 64.5 out of 100 Growth Capital Valuation Relative 46. [Magnus Steel & Infra Ltd](https://www.sectoralpha.in/stocks/magnus-steel-infra-ltd) Too little evidence to rank firmly · 40% evidence 61.1 out of 100 Growth Capital Valuation Relative 47. [Susan Electricals India Ltd](https://www.sectoralpha.in/stocks/susan-electricals-india-ltd) Too little evidence to rank firmly · 36% evidence 59.9 out of 100 Growth Capital Valuation Relative 48. Q-Line Biotech Ltd this page QLINE · quiet · Too little evidence to rank firmly · 31% evidence 59.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/43.75 · Revenue n/a · Profit n/a · Operating margin change 1 points · 26% evidence Capital efficiency 24.9/31.25 · ROCE 22.4% (year to Mar 2026) · Operating margin 26.3% · 76% evidence Valuation 13.2/25 · P/E 16.9× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 21.8 + 24.9 + 13.2 = 59.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 49. [Bizotic Commercial Ltd](https://www.sectoralpha.in/stocks/bizotic-commercial-ltd) BIZOTIC · quiet · Too little evidence to rank firmly · 38% evidence 59.4 out of 100 Growth Capital Valuation Relative 50. [Pramara Promotions Ltd](https://www.sectoralpha.in/stocks/pramara-promotions-ltd) PRAMARA · Too little evidence to rank firmly · 42% evidence 58.6 out of 100 Growth Capital Valuation Relative 51. [HP Telecom India Ltd](https://www.sectoralpha.in/stocks/hp-telecom-india-ltd) HPTL · turning · Too little evidence to rank firmly · 43% evidence 58.2 out of 100 Growth Capital Valuation Relative 52. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) turning · Too little evidence to rank firmly · 41% evidence 55.5 out of 100 Growth Capital Valuation Relative 53. [Proventus Agrocom Ltd](https://www.sectoralpha.in/stocks/proventus-agrocom-ltd) PROV · breaking out · Too little evidence to rank firmly · 50% evidence 55.1 out of 100 Growth Capital Valuation Relative 54. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) quiet · Too little evidence to rank firmly · 45% evidence 53.7 out of 100 Growth Capital Valuation Relative 55. [Monika Alcobev Ltd](https://www.sectoralpha.in/stocks/monika-alcobev-ltd) MONIKA · Too little evidence to rank firmly · 22% evidence 52.4 out of 100 Growth Capital Valuation Relative 56. [State Trading Corporation of India Ltd](https://www.sectoralpha.in/stocks/state-trading-corporation-of-india-ltd) STCINDIA · basing · Too little evidence to rank firmly · 47% evidence 50.7 out of 100 Growth Capital Valuation Relative 57. AUDROC Ltd Too little evidence to rank firmly · 43% evidence 47.1 out of 100 Growth Capital Valuation Relative 58. [Onix Solar Energy Ltd](https://www.sectoralpha.in/stocks/onix-solar-energy-ltd) ONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence 46.3 out of 100 Growth Capital Valuation Relative 59. [Arvaya Healthcare Ltd](https://www.sectoralpha.in/stocks/arvaya-healthcare-ltd) ARVAYA · turning · Too little evidence to rank firmly · 46% evidence 45.3 out of 100 Growth Capital Valuation Relative 60. C K K Retail Mart Ltd CKKRETAIL · Too little evidence to rank firmly · 36% evidence 45.3 out of 100 Growth Capital Valuation Relative 61. [Prabhatam Infra Venture Ltd](https://www.sectoralpha.in/stocks/prabhatam-infra-venture-ltd) turning · Too little evidence to rank firmly · 27% evidence 45.1 out of 100 Growth Capital Valuation Relative 62. [Satani Bearings Ltd](https://www.sectoralpha.in/stocks/satani-bearings-ltd) breaking out · Too little evidence to rank firmly · 43% evidence 43.0 out of 100 Growth Capital Valuation Relative 63. [Keto Motors Ltd](https://www.sectoralpha.in/stocks/keto-motors-ltd) quiet · Too little evidence to rank firmly · 43% evidence 39.8 out of 100 Growth Capital Valuation Relative 64. [Aerpace Industries Ltd](https://www.sectoralpha.in/stocks/aerpace-industries-ltd) breaking out · Too little evidence to rank firmly · 36% evidence 38.4 out of 100 Growth Capital Valuation Relative 65. [RRP Semiconductor Ltd](https://www.sectoralpha.in/stocks/rrp-semiconductor-ltd) RRP · Too little evidence to rank firmly · 47% evidence 35.6 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Trading](https://www.sectoralpha.in/sectors/trading), all 65 compared on one page. ## Which companies are close to Q-Line Biotech in size? Q-Line Biotech is the 21st largest of 61 Trading companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Aerpace Industries, Dhunseri Ventures and Tembo Global Industries. Just below it: Onix Solar Energy, Hexa Tradex and Aptus Pharma. ### Trading companies close in size 1. [Aerpace Industries Ltd](https://www.sectoralpha.in/stocks/aerpace-industries-ltd) ₹1,185 crore 2. [Dhunseri Ventures Ltd](https://www.sectoralpha.in/stocks/dhunseri-ventures-ltd) ₹1,081 crore 3. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) ₹970 crore 4. Q-Line Biotech Ltd ₹926 crore 5. [Onix Solar Energy Ltd](https://www.sectoralpha.in/stocks/onix-solar-energy-ltd) ₹922 crore 6. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) ₹845 crore 7. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) ₹836 crore [All 61 Trading companies, largest first](https://www.sectoralpha.in/sectors/trading#all-companies) ### Companies close in size in other industries 1. [RSWM Ltd](https://www.sectoralpha.in/stocks/rswm-ltd) ₹929 crore · Textiles - Spinning 2. [SEPC Ltd](https://www.sectoralpha.in/stocks/sepc-ltd) ₹929 crore · Project Consultancy/Turnkey 3. Q-Line Biotech Ltd ₹926 crore 4. [Onida Electronics Ltd](https://www.sectoralpha.in/stocks/onida-electronics-ltd) ₹924 crore · Consumer Electronics 5. [The Hi-Tech Gears Ltd](https://www.sectoralpha.in/stocks/the-hi-tech-gears-ltd) ₹923 crore · Auto Ancillaries - Gears ## What else do people ask about Q-Line Biotech? ### What were Q-Line Biotech's latest quarterly results? Q-Line Biotech Ltd reported revenue of ₹152 Cr and net profit of ₹20.0 Cr for the Sep 2026 quarter. Revenue rose 5.6% and profit fell 4.8% compared with a year earlier. Earnings per share were ₹8.40. The operating margin was 26.3%, 1.3 percentage points higher than a year earlier (as of 20 November 2026). ### What is Q-Line Biotech's market cap? Q-Line Biotech Ltd's market capitalisation is ₹926 Cr at a share price of ₹396.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 20 November 2026). ### How is Q-Line Biotech performing? Q-Line Biotech Ltd's share price is in an uptrend that has just slipped below its 200-day average. In its latest quarter, revenue rose 5.6% and profit fell 4.8% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running (as of 20 November 2026). ### Will Q-Line Biotech's share price go up? This page does not forecast Q-Line Biotech Ltd's share price. What it shows instead: the share price is ₹396.80, and it has been rising for 22 weeks. Its P/E of 16.9× is higher than 0% of its own last 1 years (as of 20 November 2026). ### Who owns Q-Line Biotech? Promoters own 67.5% of Q-Line Biotech Ltd, foreign institutions 0.9%, domestic institutions 8.2% and the public 23.4% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 20 November 2026). ### Where is Q-Line Biotech in its business cycle? Q-Line Biotech Ltd's FY26 operating margin was 28.7%, against a 4-year range of 18.6% to 28.7%. The latest quarter was 26.3%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 20 November 2026). ### What could break the Q-Line Biotech story? Biggest thing to watch: the price has just slipped below its 200-day average after an uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 20 November 2026). ### Is Q-Line Biotech a stock worth studying right now? What the numbers show: Q-Line Biotech Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 20 November 2026). ### Is there a Q-Line Biotech share price forecast for 2026? What management itself guided: FY27 and FY28 revenue growth 25-30% each year led by reagents, instruments and CDMO. This is research, not advice. We’re not SEBI-registered.